UNSPSC 51271806: Eticyclidine

This classification denotes an anesthetic agent with the molecular formula C14H21N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O8I1LL6A89, chemically known as cyclohexylamine, n-ethyl-1-phenyl- (8ci) but generally known as eticyclidine, which bears US NIH Compound Identifier 16622. European Medicines Agency schedules Eticyclidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07297MIG. The term ETICYCLIDINE is an International Non-Proprietary Name.

UNSPSC 51271806 Eticyclidine is a Commodity code for a controlled pharmaceutical substance that sees minimal recent state and local procurement activity. The single identifiable recent opportunity, Minnesota's MMCAP generic multi-source pharmaceuticals RFP posted in January 2026, treats eticyclidine as one line item within a much broader solicitation for generic drugs and OTC products distributed across participating state and local facilities in Minnesota and Oregon. State and local governments procure pharmaceutical supplies through cooperative purchasing vehicles like MMCAP, which aggregate demand across multiple member jurisdictions and route awards through authorized wholesalers rather than direct-to-agency channels. The Minnesota Department of Administration's Office of State Procurement administers MMCAP, and the structure—requiring vendors to work with AmerisourceBergen, Cardinal Health, and Morris & Dickson as authorized distributors—suggests that actual procurement volumes and pricing flow through these wholesale intermediaries rather than appearing as direct state or local purchases.

The geographic activity is concentrated in the Upper Midwest, with Minnesota as the administrative hub and Oregon as a named participating state in the MMCAP alliance as of early 2026. The representative recent opportunity is the MMCAP RFP S1070000015802 (response deadline March 26, 2026) seeking manufacturers to supply generic pharmaceuticals and OTC products with specific National Drug Codes, pricing evaluated on price competitiveness (75 percent weight), fixed pricing structure, EDI capability, and administrative fee compliance. Vendors must maintain relationships with at least two of three authorized wholesalers, carry cGMP and DSCSA certifications, and comply with performance penalties ranging from $200 to $1,500 per violation. The contract term is two years for new vendors with optional extensions, effective July 1, 2026. No specific dollar values or set-aside designations appear in the solicitation materials.